Background Xpert MTB/RIF (Xpert) is a promising new rapid diagnostic technology for
tuberculosis (TB) that has characteristics that suggest large-scale roll-out. However, because the …

Early in the COVID-19 pandemic, models predicted hundreds of thousands of additional TB
deaths as a result of health service disruption. To date, empirical evidence on the effects of …

Background The post-2015 End TB Strategy proposes targets of 50% reduction in tuberculosis
incidence and 75% reduction in mortality from tuberculosis by 2025. We aimed to assess …

The COVID-19 pandemic is well into its second year, but countries are only beginning to
grapple with the lasting health crisis. In March, a UK consortium reported that 1 in 5 people who …

Tuberculosis can be treated, prevented, and cured. Rapid, sustained declines in tuberculosis
deaths in many countries during the past 50 years provide compelling evidence that …

Background Cost-effectiveness studies inform resource allocation, strategy, and policy
development. However, due to their complexity, dependence on assumptions made, and inherent …

Background In South Africa, sputum smear microscopy has been replaced with Xpert MTB/RIF
as the initial diagnostic test for tuberculosis. In a pragmatic parallel cluster-randomised …

Background Novel tuberculosis (TB) drugs and the need to treat drug-resistant tuberculosis (DR-TB)
are likely to bring about substantial transformations in TB treatment in coming years. …

Social protection against the cost of illness is a central policy objective of Universal Health
Coverage and the post-2015 Global strategy for Tuberculosis (TB). Understanding the …

Tropical diseases are infectious diseases that are found predominantly in the tropics, where
ecological and socioeconomic conditions facilitate their propagation. Climatic, social, and …